Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
February 29, 2024NEW YORK, February 29, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
February 22, 2024– Significantly Strengthened Balance Sheet in January 2024 with Execution of Three-Tranche Private Placement of up to $240 Million, Extending…Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 15, 2024– Webcast to be Held at 8:00 am ET on February 22, 2024 – NEW YORK, February 15, 2024 – Immunic,…Immunic to Participate in Investor and Scientific Conferences in February
February 1, 2024NEW YORK, February 1, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered,…Immunic Highlights 2023 Accomplishments and Upcoming Milestones
January 5, 2024– Evidence for Neuroprotective Activity of Vidofludimus Calcium from Phase 2 CALLIPER Interim Analysis, Consistent Across the Entire Progressive Multiple…Immunic, Inc. Announces Private Placement of up to $240 Million
January 5, 2024NEW YORK, January 5, 2024 – Immunic, Inc. (Nasdaq: IMUX) (“Immunic” or the “Company”), a biotechnology company developing a clinical…